Arcturus Therapeutics Holdings Inc.

NasdaqGM:ARCT 주식 보고서

시가총액: US$438.0m

Arcturus Therapeutics Holdings 미래 성장

Future 기준 확인 5/6

Arcturus Therapeutics Holdings (는) 각각 연간 70.8% 및 35.3% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 70.3% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 -157.6% 로 예상됩니다.

주요 정보

70.8%

수익 성장률

70.3%

EPS 성장률

Biotechs 수익 성장28.4%
매출 성장률35.3%
향후 자기자본 수익률-157.6%
애널리스트 커버리지

Good

마지막 업데이트08 Nov 2024

최근 미래 성장 업데이트

Recent updates

Arcturus: LUNAR-CF For CF Presses On With 1st Half Of 2025 Interim Data

Nov 14

Improved Revenues Required Before Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Stock's 28% Jump Looks Justified

Oct 04
Improved Revenues Required Before Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Stock's 28% Jump Looks Justified

Here's Why We're Not Too Worried About Arcturus Therapeutics Holdings' (NASDAQ:ARCT) Cash Burn Situation

Sep 06
Here's Why We're Not Too Worried About Arcturus Therapeutics Holdings' (NASDAQ:ARCT) Cash Burn Situation

High-Risk, High-Reward: Arcturus Nears Commercialization Of Kostaive Vaccine

Aug 09

Arcturus: A Hidden Gem In The Biotech Sector

Jun 08

Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Share Price Boosted 45% But Its Business Prospects Need A Lift Too

May 29
Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Share Price Boosted 45% But Its Business Prospects Need A Lift Too

Arcturus Therapeutics' ARCT-032: Might Be The Next Breakthrough In Cystic Fibrosis

Apr 23

Arcturus Therapeutics Holdings (NASDAQ:ARCT) Is In A Strong Position To Grow Its Business

Apr 09
Arcturus Therapeutics Holdings (NASDAQ:ARCT) Is In A Strong Position To Grow Its Business

Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Price Is Right But Growth Is Lacking

Feb 06
Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Price Is Right But Growth Is Lacking

Arcturus: H1 2024 Rare Disease Drug Data On Deck

Jan 31

Does Arcturus Therapeutics Holdings (NASDAQ:ARCT) Have A Healthy Balance Sheet?

Jan 11
Does Arcturus Therapeutics Holdings (NASDAQ:ARCT) Have A Healthy Balance Sheet?

Are Investors Undervaluing Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) By 46%?

Dec 14
Are Investors Undervaluing Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) By 46%?

Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Shares Lagging The Industry But So Is The Business

Sep 14
Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Shares Lagging The Industry But So Is The Business

Some Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Analysts Just Made A Major Cut To Next Year's Estimates

Aug 08
Some Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Analysts Just Made A Major Cut To Next Year's Estimates

Calculating The Fair Value Of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Jul 19
Calculating The Fair Value Of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Broker Revenue Forecasts For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Are Surging Higher

May 18
Broker Revenue Forecasts For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Are Surging Higher

Arcturus Therapeutics Holdings (NASDAQ:ARCT) Has A Rock Solid Balance Sheet

May 02
Arcturus Therapeutics Holdings (NASDAQ:ARCT) Has A Rock Solid Balance Sheet

Here's Why Arcturus Therapeutics Holdings (NASDAQ:ARCT) Can Manage Its Debt Despite Losing Money

Dec 28
Here's Why Arcturus Therapeutics Holdings (NASDAQ:ARCT) Can Manage Its Debt Despite Losing Money

Arcturus Therapeutics Holdings (NASDAQ:ARCT) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Sep 23
Arcturus Therapeutics Holdings (NASDAQ:ARCT) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Arcturus rises 6% on $63.2M award from U.S. government for mRNA vaccine

Aug 31

Analysts Just Published A Bright New Outlook For Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT)

Aug 15
Analysts Just Published A Bright New Outlook For Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT)

Arcturus Therapeutics downgraded to underperform at Raymond James on program setbacks

Aug 10

Arcturus: Potential Based On Rare Disease Therapy ARCT-810

Jun 07

수익 및 매출 성장 예측

NasdaqGM:ARCT - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
12/31/202635149-151N/A8
12/31/2025214-47-192N/A10
12/31/2024175-64N/AN/A10
9/30/2024160-63-62-60N/A
6/30/2024164-72-71-69N/A
3/31/2024125-1071012N/A
12/31/2023167-30-21-18N/A
9/30/202329699137143N/A
6/30/202326480126133N/A
3/31/20232811113945N/A
12/31/202220692432N/A
9/30/202252-147-176-171N/A
6/30/202241-165-150-145N/A
3/31/202215-198-147-141N/A
12/31/202112-204-138-135N/A
9/30/20219-196-102-99N/A
6/30/20219-163-100-98N/A
3/31/20219-119-76-74N/A
12/31/202010-72-45-43N/A
9/30/202010-52-45-44N/A
6/30/202011-38-32-31N/A
3/31/202019-29-14-13N/A
12/31/201921-26-7-6N/A
9/30/201925-16-5-5N/A
6/30/201926-13-9-9N/A
3/31/201918-22-27-26N/A
12/31/201816-22-22-21N/A
9/30/201810-26-11-10N/A
6/30/201810-25N/A-5N/A
3/31/201812-16N/A1N/A
12/31/201713-11N/A0N/A
12/31/201620-2N/A-3N/A
12/31/20156-2N/A8N/A

애널리스트 미래 성장 예측

수입 대 저축률: ARCT 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률( 2.6% )보다 빠른 성장으로 간주됩니다.

수익 vs 시장: ARCT (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.

고성장 수익: ARCT 향후 3년 내에 수익을 낼 것으로 예상됩니다.

수익 대 시장: ARCT 의 수익(연간 35.3% ) US 시장( 9% 보다 빠르게 성장할 것으로 예상됩니다. 9% 연간).

고성장 수익: ARCT 의 수익(연간 35.3% )은 연간 20% 보다 빠르게 증가할 것으로 예상됩니다.


주당 순이익 성장 예측


미래 자기자본 수익률

미래 ROE: ARCT (는) 3년 내에 수익성이 없을 것으로 예상됩니다.


성장 기업 발견